PixCell signs European distribution agreement with Axonlab for HemoScreen
PixCell Medical, a rapid diagnostic solutions developer, has struck a distribution agreement with Axonlab, a point-of-care testing company in Europe to distribute the HemoScreen, PixCell’s haematology analyser, in certain European countries.
Axonlab will have exclusive distribution rights in Switzerland, Austria, the Netherlands and the Czech Republic.
Dr Tamara Hensel, chief sales & marketing officer at Axonlab, said: “Collaborating with reputable international supply partners to provide innovative diagnostic systems to clinics, doctors and the research sector is central to our identity as a company. We focus on delivering comprehensive, future-oriented services, and believe that PixCell’s HemoScreen is an important tool to enhance a clinician’s diagnostic and decision-making capabilities. AI-driven diagnostic tools such as the HemoScreen represent the next evolution of diagnostic technologies. Making this technology available at the point of care for hospitals, medical practices, pharmacies, private laboratories and research organisations can increase patient safety, reduce delays in receiving key diagnostic results, and support clinicians in making informed decisions.”
HemoScreen, developed by PixCell Medical, is a five-part differential Complete Blood Count (CBC) analyser that is both FDA-cleared and CE-marked for point-of-care use. HemoScreen delivers lab-quality diagnostic results equivalent to the large and complex lab analysers traditionally used for haematological testing in significantly less time. Utilising a disposable cartridge preloaded with all necessary reagents, HemoScreen eliminates the need for routine maintenance and calibration and does not need to be operated by a lab technician. With one drop of blood and within six minutes, HemoScreen delivers CBC results with 20 standard CBC parameters as well as comprehensive abnormal cell flagging for earlier detection of infection and certain cancer types.
Dr. Avishay Bransky, CEO of PixCell Medical, said: “Making HemoScreen widely available enables healthcare organisations to maximise diagnostic resources and helps physicians make faster and more educated clinical decisions. Ultimately, we want to increase efficiency of diagnostics while maintaining the precision of result to help improve patient care and outcomes in a variety of point-of-care settings, including the ICU, emergency departments and oncology wards. We are proud to collaborate with one of the most important distributers of point-of-care testing in Europe, a company known for its uncompromising quality. We are confident that Axonlab will serve as an excellent partner and help to dramatically improve the accessibility of the CBC, the most essential blood test, within the markets it serves.”